Settleman J - Search Results

1

mTORC1-Dependent Metabolic Reprogramming Underlies Escape from Glycolysis Addiction in Cancer Cells.

Pusapati RV, Daemen A, Wilson C, Sandoval W, Gao M, Haley B, Baudy AR, Hatzivassiliou G, Evangelista M, Settleman J. Pusapati RV, et al. Among authors: settleman j. Cancer Cell. 2016 Apr 11;29(4):548-562. doi: 10.1016/j.ccell.2016.02.018. Epub 2016 Mar 24. Cancer Cell. 2016. PMID: 27052953 Free article.

2

A therapeutic opportunity in melanoma: ErbB4 makes a mark on skin.

Settleman J. Settleman J. Cancer Cell. 2009 Oct 6;16(4):278-9. doi: 10.1016/j.ccr.2009.09.013. Cancer Cell. 2009. PMID: 19800573 Free article.

3

Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency.

McDermott U, Pusapati RV, Christensen JG, Gray NS, Settleman J. McDermott U, et al. Among authors: settleman j. Cancer Res. 2010 Feb 15;70(4):1625-34. doi: 10.1158/0008-5472.CAN-09-3620. Epub 2010 Feb 2. Cancer Res. 2010. PMID: 20124471 Free PMC article.

4

Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy.

Sun Y, Wang BE, Leong KG, Yue P, Li L, Jhunjhunwala S, Chen D, Seo K, Modrusan Z, Gao WQ, Settleman J, Johnson L. Sun Y, et al. Among authors: settleman j. Cancer Res. 2012 Jan 15;72(2):527-36. doi: 10.1158/0008-5472.CAN-11-3004. Epub 2011 Nov 22. Cancer Res. 2012. PMID: 22108827

5

Noncovalent wild-type-sparing inhibitors of EGFR T790M.

Lee HJ, Schaefer G, Heffron TP, Shao L, Ye X, Sideris S, Malek S, Chan E, Merchant M, La H, Ubhayakar S, Yauch RL, Pirazzoli V, Politi K, Settleman J. Lee HJ, et al. Among authors: settleman j. Cancer Discov. 2013 Feb;3(2):168-81. doi: 10.1158/2159-8290.CD-12-0357. Epub 2012 Dec 10. Cancer Discov. 2013. PMID: 23229345 Free PMC article.

6

Comparative oncogenomics identifies PSMB4 and SHMT2 as potential cancer driver genes.

Lee GY, Haverty PM, Li L, Kljavin NM, Bourgon R, Lee J, Stern H, Modrusan Z, Seshagiri S, Zhang Z, Davis D, Stokoe D, Settleman J, de Sauvage FJ, Neve RM. Lee GY, et al. Among authors: settleman j. Cancer Res. 2014 Jun 1;74(11):3114-26. doi: 10.1158/0008-5472.CAN-13-2683. Epub 2014 Apr 22. Cancer Res. 2014. PMID: 24755469

7

The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation.

Raha D, Wilson TR, Peng J, Peterson D, Yue P, Evangelista M, Wilson C, Merchant M, Settleman J. Raha D, et al. Among authors: settleman j. Cancer Res. 2014 Jul 1;74(13):3579-90. doi: 10.1158/0008-5472.CAN-13-3456. Epub 2014 May 8. Cancer Res. 2014. PMID: 24812274

8

From cancer genomics to precision oncology--tissue's still an issue.

Cohen RL, Settleman J. Cohen RL, et al. Among authors: settleman j. Cell. 2014 Jun 19;157(7):1509-14. doi: 10.1016/j.cell.2014.05.027. Cell. 2014. PMID: 24949964 Free article.

9

Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells.

Lee HJ, Zhuang G, Cao Y, Du P, Kim HJ, Settleman J. Lee HJ, et al. Among authors: settleman j. Cancer Cell. 2014 Aug 11;26(2):207-21. doi: 10.1016/j.ccr.2014.05.019. Epub 2014 Jul 24. Cancer Cell. 2014. PMID: 25065853 Free article.

10

AXL inhibition sensitizes mesenchymal cancer cells to antimitotic drugs.

Wilson C, Ye X, Pham T, Lin E, Chan S, McNamara E, Neve RM, Belmont L, Koeppen H, Yauch RL, Ashkenazi A, Settleman J. Wilson C, et al. Among authors: settleman j. Cancer Res. 2014 Oct 15;74(20):5878-90. doi: 10.1158/0008-5472.CAN-14-1009. Epub 2014 Aug 14. Cancer Res. 2014. PMID: 25125659

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

238 results

Search Page